Rheumatology Therapeutics

Global Market Trajectory & Analytics

MCP16758

EXECUTIVE ENGAGEMENTS

POOL

5142
Number of executives repeatedly engaged by snail & email outreach

INTERACTIONS

822
Interactions with Platform & by Email

PARTICIPANTS

154
Unique # Participated

VALIDATIONS

33
Responses Validated*

COMPANIES

46
Responses Validated*
* Login for a full stack data experience

DATE

JAN 2022

TABLES

123

PAGES

196

EDITION

7

PRICE

USD 5450

CODE

MCP16758


COMPETITIVE METRICS

COMPETITORS (ALPHABETICAL)

S M N T

%

VALIDATED RESEARCH *

S M N T
S M N T
S M N T
S M N T
S M N T
S M N T
S M N T
S M N T
S M N T
S M N T

* S = Strong; M = Moderate; N = Niche; T= Trivial (<1%)
* Login to Participate & View Data Stacks
* Participating executives must be from a competitive company. Executive credentials are validated by a one-time two-factor authentication, in compliance with GDPR guidelines. Verified executives have complimentary access to our proprietary MarketGlassTM platform and relevant data silos including Trend Data; Brand/IP/TM Feeds; and Market Size, Share & Rank Clusters. Qualified influencers are also invited to join our Expert Panels. Privileges include purchase credits, and collaborative bespoke builds.
View All Companies...

PARTICIPATE NOW!
  

HIGHLIGHTS & REPORT INDEX

Amid the COVID-19 crisis, the global market for Rheumatology Therapeutics estimated at US$45.1 Billion in the year 2020, is projected to reach a revised size of US$53.7 Billion by 2027, growing at a CAGR of 2.5% over the analysis period 2020-2027. Disease Modifying Anti-Rheumatic Drugs (DMARDs), one of the segments analyzed in the report, is projected to record a 2.4% CAGR and reach US$45.7 Billion by the end of the analysis period. After an early analysis of the business implications of the pandemic and its induced economic crisis, growth in the Non-Steroidal Anti-Inflammatory Drugs (Nsaids) segment is readjusted to a revised 3% CAGR for the next 7-year period.
The Rheumatology Therapeutics market in the U.S. is estimated at US$13.2 Billion in the year 2020. China, the world`s second largest economy, is forecast to reach a projected market size of US$9.6 Billion by the year 2027 trailing a CAGR of 2.4% over the analysis period 2020 to 2027. Among the other noteworthy geographic markets are Japan and Canada, each forecast to grow at 2.4% and 2.1% respectively over the 2020-2027 period. Within Europe, Germany is forecast to grow at approximately 2.7% CAGR.
In the global Corticosteroids segment, USA, Canada, Japan, China and Europe will drive the 3.8% CAGR estimated for this segment. These regional markets accounting for a combined market size of US$1.4 Billion in the year 2020 will reach a projected size of US$1.8 Billion by the close of the analysis period. China will remain among the fastest growing in this cluster of regional markets. Led by countries such as Australia, India, and South Korea, the market in Asia-Pacific is forecast to reach US$6 Billion by the year 2027.

SELECT PLAYERS

AbbVie, Inc.; Amgen, Inc.; Bristol-Myers Squibb Company; Genentech, Inc.; Janssen Biotech, Inc.; Merck & Co., Inc.; Novartis AG; Pfizer, Inc.; Sanofi SA; Takeda Pharmaceutical Co., Ltd.

SEGMENTS

» Disease Indication (Rheumatoid Arthritis (RA), Osteoarthritis (OA), Gout, Ankylosing Spondylitis, Psoriatic Arthritis, Other Disease Indications) » Distribution Channel (Hospital Pharmacy, Retail Pharmacy, Online Pharmacy) » Drug Class (Disease Modifying Anti-Rheumatic Drugs (DMARDs), Non-Steroidal Anti-Inflammatory Drugs (Nsaids), Corticosteroids, Uric Acid Drugs, Other Drug Classes) » Route of Administration (Oral Route, Parenteral Route, Topical)

GEOGRAPHIES

» World » United States » Canada » Japan » China » Europe » France » Germany » Italy » United Kingdom » and Rest of Europe » Asia-Pacific » Rest of World

TABLE OF CONTENTS

1. MARKET OVERVIEW
Influencer Market Insights
World Market Trajectories
Impact of Covid-19 and a Looming Global Recession
2. FOCUS ON SELECT PLAYERS
3. MARKET TRENDS & DRIVERS
4. GLOBAL MARKET PERSPECTIVE
World Current & Future Analysis for Rheumatology Therapeutics by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Million for Years 2020 through 2027 and % CAGR
World Historic Review for Rheumatology Therapeutics by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Million for Years 2012 through 2019 and % CAGR
World 15-Year Perspective for Rheumatology Therapeutics by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets for Years 2012, 2020 & 2027
World Current & Future Analysis for Disease Modifying Anti-Rheumatic Drugs (DMARDs) by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Million for Years 2020 through 2027 and % CAGR
World Historic Review for Disease Modifying Anti-Rheumatic Drugs (DMARDs) by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Million for Years 2012 through 2019 and % CAGR
World 15-Year Perspective for Disease Modifying Anti-Rheumatic Drugs (DMARDs) by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World for Years 2012, 2020 & 2027
World Current & Future Analysis for Non-Steroidal Anti-Inflammatory Drugs (Nsaids) by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Million for Years 2020 through 2027 and % CAGR
World Historic Review for Non-Steroidal Anti-Inflammatory Drugs (Nsaids) by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Million for Years 2012 through 2019 and % CAGR
World 15-Year Perspective for Non-Steroidal Anti-Inflammatory Drugs (Nsaids) by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World for Years 2012, 2020 & 2027
World Current & Future Analysis for Corticosteroids by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Million for Years 2020 through 2027 and % CAGR
World Historic Review for Corticosteroids by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Million for Years 2012 through 2019 and % CAGR
World 15-Year Perspective for Corticosteroids by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World for Years 2012, 2020 & 2027
World Current & Future Analysis for Uric Acid Drugs by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Million for Years 2020 through 2027 and % CAGR
World Historic Review for Uric Acid Drugs by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Million for Years 2012 through 2019 and % CAGR
World 15-Year Perspective for Uric Acid Drugs by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World for Years 2012, 2020 & 2027
World Current & Future Analysis for Other Drug Classes by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Million for Years 2020 through 2027 and % CAGR
World Historic Review for Other Drug Classes by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Million for Years 2012 through 2019 and % CAGR
World 15-Year Perspective for Other Drug Classes by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World for Years 2012, 2020 & 2027
World Current & Future Analysis for Osteoarthritis (OA) by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Million for Years 2020 through 2027 and % CAGR
World Historic Review for Osteoarthritis (OA) by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Million for Years 2012 through 2019 and % CAGR
World 15-Year Perspective for Osteoarthritis (OA) by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World for Years 2012, 2020 & 2027
World Current & Future Analysis for Rheumatoid Arthritis (RA) by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Million for Years 2020 through 2027 and % CAGR
World Historic Review for Rheumatoid Arthritis (RA) by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Million for Years 2012 through 2019 and % CAGR
World 15-Year Perspective for Rheumatoid Arthritis (RA) by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World for Years 2012, 2020 & 2027
World Current & Future Analysis for Gout by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Million for Years 2020 through 2027 and % CAGR
World Historic Review for Gout by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Million for Years 2012 through 2019 and % CAGR
World 15-Year Perspective for Gout by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World for Years 2012, 2020 & 2027
World Current & Future Analysis for Ankylosing Spondylitis by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Million for Years 2020 through 2027 and % CAGR
World Historic Review for Ankylosing Spondylitis by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Million for Years 2012 through 2019 and % CAGR
World 15-Year Perspective for Ankylosing Spondylitis by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World for Years 2012, 2020 & 2027
World Current & Future Analysis for Psoriatic Arthritis by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Million for Years 2020 through 2027 and % CAGR
World Historic Review for Psoriatic Arthritis by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Million for Years 2012 through 2019 and % CAGR
World 15-Year Perspective for Psoriatic Arthritis by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World for Years 2012, 2020 & 2027
World Current & Future Analysis for Other Disease Indications by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Million for Years 2020 through 2027 and % CAGR
World Historic Review for Other Disease Indications by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Million for Years 2012 through 2019 and % CAGR
World 15-Year Perspective for Other Disease Indications by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World for Years 2012, 2020 & 2027
World Current & Future Analysis for Oral Route by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Million for Years 2020 through 2027 and % CAGR
World Historic Review for Oral Route by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Million for Years 2012 through 2019 and % CAGR
World 15-Year Perspective for Oral Route by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World for Years 2012, 2020 & 2027
World Current & Future Analysis for Parenteral Route by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Million for Years 2020 through 2027 and % CAGR
World Historic Review for Parenteral Route by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Million for Years 2012 through 2019 and % CAGR
World 15-Year Perspective for Parenteral Route by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World for Years 2012, 2020 & 2027
World Current & Future Analysis for Topical by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Million for Years 2020 through 2027 and % CAGR
World Historic Review for Topical by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Million for Years 2012 through 2019 and % CAGR
World 15-Year Perspective for Topical by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World for Years 2012, 2020 & 2027
World Current & Future Analysis for Hospital Pharmacy by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Million for Years 2020 through 2027 and % CAGR
World Historic Review for Hospital Pharmacy by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Million for Years 2012 through 2019 and % CAGR
World 15-Year Perspective for Hospital Pharmacy by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World for Years 2012, 2020 & 2027
World Current & Future Analysis for Retail Pharmacy by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Million for Years 2020 through 2027 and % CAGR
World Historic Review for Retail Pharmacy by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Million for Years 2012 through 2019 and % CAGR
World 15-Year Perspective for Retail Pharmacy by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World for Years 2012, 2020 & 2027
World Current & Future Analysis for Online Pharmacy by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Million for Years 2020 through 2027 and % CAGR
World Historic Review for Online Pharmacy by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Million for Years 2012 through 2019 and % CAGR
World 15-Year Perspective for Online Pharmacy by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World for Years 2012, 2020 & 2027
UNITED STATES
USA Current & Future Analysis for Rheumatology Therapeutics by Drug Class - Disease Modifying Anti-Rheumatic Drugs (DMARDs), Non-Steroidal Anti-Inflammatory Drugs (Nsaids), Corticosteroids, Uric Acid Drugs and Other Drug Classes - Independent Analysis of Annual Sales in US$ Million for the Years 2020 through 2027 and % CAGR
USA Historic Review for Rheumatology Therapeutics by Drug Class - Disease Modifying Anti-Rheumatic Drugs (DMARDs), Non-Steroidal Anti-Inflammatory Drugs (Nsaids), Corticosteroids, Uric Acid Drugs and Other Drug Classes Markets - Independent Analysis of Annual Sales in US$ Million for Years 2012 through 2019 and % CAGR
USA 15-Year Perspective for Rheumatology Therapeutics by Drug Class - Percentage Breakdown of Value Sales for Disease Modifying Anti-Rheumatic Drugs (DMARDs), Non-Steroidal Anti-Inflammatory Drugs (Nsaids), Corticosteroids, Uric Acid Drugs and Other Drug Classes for the Years 2012, 2020 & 2027
USA Current & Future Analysis for Rheumatology Therapeutics by Disease Indication - Rheumatoid Arthritis (RA), Osteoarthritis (OA), Gout, Ankylosing Spondylitis, Psoriatic Arthritis and Other Disease Indications - Independent Analysis of Annual Sales in US$ Million for the Years 2020 through 2027 and % CAGR
USA Historic Review for Rheumatology Therapeutics by Disease Indication - Rheumatoid Arthritis (RA), Osteoarthritis (OA), Gout, Ankylosing Spondylitis, Psoriatic Arthritis and Other Disease Indications Markets - Independent Analysis of Annual Sales in US$ Million for Years 2012 through 2019 and % CAGR
USA 15-Year Perspective for Rheumatology Therapeutics by Disease Indication - Percentage Breakdown of Value Sales for Rheumatoid Arthritis (RA), Osteoarthritis (OA), Gout, Ankylosing Spondylitis, Psoriatic Arthritis and Other Disease Indications for the Years 2012, 2020 & 2027
USA Current & Future Analysis for Rheumatology Therapeutics by Route Of Administration - Oral Route, Parenteral Route and Topical - Independent Analysis of Annual Sales in US$ Million for the Years 2020 through 2027 and % CAGR
USA Historic Review for Rheumatology Therapeutics by Route Of Administration - Oral Route, Parenteral Route and Topical Markets - Independent Analysis of Annual Sales in US$ Million for Years 2012 through 2019 and % CAGR
USA 15-Year Perspective for Rheumatology Therapeutics by Route Of Administration - Percentage Breakdown of Value Sales for Oral Route, Parenteral Route and Topical for the Years 2012, 2020 & 2027
USA Current & Future Analysis for Rheumatology Therapeutics by Distribution Channel - Hospital Pharmacy, Retail Pharmacy and Online Pharmacy - Independent Analysis of Annual Sales in US$ Million for the Years 2020 through 2027 and % CAGR
USA Historic Review for Rheumatology Therapeutics by Distribution Channel - Hospital Pharmacy, Retail Pharmacy and Online Pharmacy Markets - Independent Analysis of Annual Sales in US$ Million for Years 2012 through 2019 and % CAGR
USA 15-Year Perspective for Rheumatology Therapeutics by Distribution Channel - Percentage Breakdown of Value Sales for Hospital Pharmacy, Retail Pharmacy and Online Pharmacy for the Years 2012, 2020 & 2027
CANADA
Canada Current & Future Analysis for Rheumatology Therapeutics by Drug Class - Disease Modifying Anti-Rheumatic Drugs (DMARDs), Non-Steroidal Anti-Inflammatory Drugs (Nsaids), Corticosteroids, Uric Acid Drugs and Other Drug Classes - Independent Analysis of Annual Sales in US$ Million for the Years 2020 through 2027 and % CAGR
Canada Historic Review for Rheumatology Therapeutics by Drug Class - Disease Modifying Anti-Rheumatic Drugs (DMARDs), Non-Steroidal Anti-Inflammatory Drugs (Nsaids), Corticosteroids, Uric Acid Drugs and Other Drug Classes Markets - Independent Analysis of Annual Sales in US$ Million for Years 2012 through 2019 and % CAGR
Canada 15-Year Perspective for Rheumatology Therapeutics by Drug Class - Percentage Breakdown of Value Sales for Disease Modifying Anti-Rheumatic Drugs (DMARDs), Non-Steroidal Anti-Inflammatory Drugs (Nsaids), Corticosteroids, Uric Acid Drugs and Other Drug Classes for the Years 2012, 2020 & 2027
Canada Current & Future Analysis for Rheumatology Therapeutics by Disease Indication - Rheumatoid Arthritis (RA), Osteoarthritis (OA), Gout, Ankylosing Spondylitis, Psoriatic Arthritis and Other Disease Indications - Independent Analysis of Annual Sales in US$ Million for the Years 2020 through 2027 and % CAGR
Canada Historic Review for Rheumatology Therapeutics by Disease Indication - Rheumatoid Arthritis (RA), Osteoarthritis (OA), Gout, Ankylosing Spondylitis, Psoriatic Arthritis and Other Disease Indications Markets - Independent Analysis of Annual Sales in US$ Million for Years 2012 through 2019 and % CAGR
Canada 15-Year Perspective for Rheumatology Therapeutics by Disease Indication - Percentage Breakdown of Value Sales for Rheumatoid Arthritis (RA), Osteoarthritis (OA), Gout, Ankylosing Spondylitis, Psoriatic Arthritis and Other Disease Indications for the Years 2012, 2020 & 2027
Canada Current & Future Analysis for Rheumatology Therapeutics by Route Of Administration - Oral Route, Parenteral Route and Topical - Independent Analysis of Annual Sales in US$ Million for the Years 2020 through 2027 and % CAGR
Canada Historic Review for Rheumatology Therapeutics by Route Of Administration - Oral Route, Parenteral Route and Topical Markets - Independent Analysis of Annual Sales in US$ Million for Years 2012 through 2019 and % CAGR
Canada 15-Year Perspective for Rheumatology Therapeutics by Route Of Administration - Percentage Breakdown of Value Sales for Oral Route, Parenteral Route and Topical for the Years 2012, 2020 & 2027
Canada Current & Future Analysis for Rheumatology Therapeutics by Distribution Channel - Hospital Pharmacy, Retail Pharmacy and Online Pharmacy - Independent Analysis of Annual Sales in US$ Million for the Years 2020 through 2027 and % CAGR
Canada Historic Review for Rheumatology Therapeutics by Distribution Channel - Hospital Pharmacy, Retail Pharmacy and Online Pharmacy Markets - Independent Analysis of Annual Sales in US$ Million for Years 2012 through 2019 and % CAGR
Canada 15-Year Perspective for Rheumatology Therapeutics by Distribution Channel - Percentage Breakdown of Value Sales for Hospital Pharmacy, Retail Pharmacy and Online Pharmacy for the Years 2012, 2020 & 2027
JAPAN
Japan Current & Future Analysis for Rheumatology Therapeutics by Drug Class - Disease Modifying Anti-Rheumatic Drugs (DMARDs), Non-Steroidal Anti-Inflammatory Drugs (Nsaids), Corticosteroids, Uric Acid Drugs and Other Drug Classes - Independent Analysis of Annual Sales in US$ Million for the Years 2020 through 2027 and % CAGR
Japan Historic Review for Rheumatology Therapeutics by Drug Class - Disease Modifying Anti-Rheumatic Drugs (DMARDs), Non-Steroidal Anti-Inflammatory Drugs (Nsaids), Corticosteroids, Uric Acid Drugs and Other Drug Classes Markets - Independent Analysis of Annual Sales in US$ Million for Years 2012 through 2019 and % CAGR
Japan 15-Year Perspective for Rheumatology Therapeutics by Drug Class - Percentage Breakdown of Value Sales for Disease Modifying Anti-Rheumatic Drugs (DMARDs), Non-Steroidal Anti-Inflammatory Drugs (Nsaids), Corticosteroids, Uric Acid Drugs and Other Drug Classes for the Years 2012, 2020 & 2027
Japan Current & Future Analysis for Rheumatology Therapeutics by Disease Indication - Rheumatoid Arthritis (RA), Osteoarthritis (OA), Gout, Ankylosing Spondylitis, Psoriatic Arthritis and Other Disease Indications - Independent Analysis of Annual Sales in US$ Million for the Years 2020 through 2027 and % CAGR
Japan Historic Review for Rheumatology Therapeutics by Disease Indication - Rheumatoid Arthritis (RA), Osteoarthritis (OA), Gout, Ankylosing Spondylitis, Psoriatic Arthritis and Other Disease Indications Markets - Independent Analysis of Annual Sales in US$ Million for Years 2012 through 2019 and % CAGR
Japan 15-Year Perspective for Rheumatology Therapeutics by Disease Indication - Percentage Breakdown of Value Sales for Rheumatoid Arthritis (RA), Osteoarthritis (OA), Gout, Ankylosing Spondylitis, Psoriatic Arthritis and Other Disease Indications for the Years 2012, 2020 & 2027
Japan Current & Future Analysis for Rheumatology Therapeutics by Route Of Administration - Oral Route, Parenteral Route and Topical - Independent Analysis of Annual Sales in US$ Million for the Years 2020 through 2027 and % CAGR
Japan Historic Review for Rheumatology Therapeutics by Route Of Administration - Oral Route, Parenteral Route and Topical Markets - Independent Analysis of Annual Sales in US$ Million for Years 2012 through 2019 and % CAGR
Japan 15-Year Perspective for Rheumatology Therapeutics by Route Of Administration - Percentage Breakdown of Value Sales for Oral Route, Parenteral Route and Topical for the Years 2012, 2020 & 2027
Japan Current & Future Analysis for Rheumatology Therapeutics by Distribution Channel - Hospital Pharmacy, Retail Pharmacy and Online Pharmacy - Independent Analysis of Annual Sales in US$ Million for the Years 2020 through 2027 and % CAGR
Japan Historic Review for Rheumatology Therapeutics by Distribution Channel - Hospital Pharmacy, Retail Pharmacy and Online Pharmacy Markets - Independent Analysis of Annual Sales in US$ Million for Years 2012 through 2019 and % CAGR
Japan 15-Year Perspective for Rheumatology Therapeutics by Distribution Channel - Percentage Breakdown of Value Sales for Hospital Pharmacy, Retail Pharmacy and Online Pharmacy for the Years 2012, 2020 & 2027
CHINA
China Current & Future Analysis for Rheumatology Therapeutics by Drug Class - Disease Modifying Anti-Rheumatic Drugs (DMARDs), Non-Steroidal Anti-Inflammatory Drugs (Nsaids), Corticosteroids, Uric Acid Drugs and Other Drug Classes - Independent Analysis of Annual Sales in US$ Million for the Years 2020 through 2027 and % CAGR
China Historic Review for Rheumatology Therapeutics by Drug Class - Disease Modifying Anti-Rheumatic Drugs (DMARDs), Non-Steroidal Anti-Inflammatory Drugs (Nsaids), Corticosteroids, Uric Acid Drugs and Other Drug Classes Markets - Independent Analysis of Annual Sales in US$ Million for Years 2012 through 2019 and % CAGR
China 15-Year Perspective for Rheumatology Therapeutics by Drug Class - Percentage Breakdown of Value Sales for Disease Modifying Anti-Rheumatic Drugs (DMARDs), Non-Steroidal Anti-Inflammatory Drugs (Nsaids), Corticosteroids, Uric Acid Drugs and Other Drug Classes for the Years 2012, 2020 & 2027
China Current & Future Analysis for Rheumatology Therapeutics by Disease Indication - Rheumatoid Arthritis (RA), Osteoarthritis (OA), Gout, Ankylosing Spondylitis, Psoriatic Arthritis and Other Disease Indications - Independent Analysis of Annual Sales in US$ Million for the Years 2020 through 2027 and % CAGR
China Historic Review for Rheumatology Therapeutics by Disease Indication - Rheumatoid Arthritis (RA), Osteoarthritis (OA), Gout, Ankylosing Spondylitis, Psoriatic Arthritis and Other Disease Indications Markets - Independent Analysis of Annual Sales in US$ Million for Years 2012 through 2019 and % CAGR
China 15-Year Perspective for Rheumatology Therapeutics by Disease Indication - Percentage Breakdown of Value Sales for Rheumatoid Arthritis (RA), Osteoarthritis (OA), Gout, Ankylosing Spondylitis, Psoriatic Arthritis and Other Disease Indications for the Years 2012, 2020 & 2027
China Current & Future Analysis for Rheumatology Therapeutics by Route Of Administration - Oral Route, Parenteral Route and Topical - Independent Analysis of Annual Sales in US$ Million for the Years 2020 through 2027 and % CAGR
China Historic Review for Rheumatology Therapeutics by Route Of Administration - Oral Route, Parenteral Route and Topical Markets - Independent Analysis of Annual Sales in US$ Million for Years 2012 through 2019 and % CAGR
China 15-Year Perspective for Rheumatology Therapeutics by Route Of Administration - Percentage Breakdown of Value Sales for Oral Route, Parenteral Route and Topical for the Years 2012, 2020 & 2027
China Current & Future Analysis for Rheumatology Therapeutics by Distribution Channel - Hospital Pharmacy, Retail Pharmacy and Online Pharmacy - Independent Analysis of Annual Sales in US$ Million for the Years 2020 through 2027 and % CAGR
China Historic Review for Rheumatology Therapeutics by Distribution Channel - Hospital Pharmacy, Retail Pharmacy and Online Pharmacy Markets - Independent Analysis of Annual Sales in US$ Million for Years 2012 through 2019 and % CAGR
China 15-Year Perspective for Rheumatology Therapeutics by Distribution Channel - Percentage Breakdown of Value Sales for Hospital Pharmacy, Retail Pharmacy and Online Pharmacy for the Years 2012, 2020 & 2027
EUROPE
Europe Current & Future Analysis for Rheumatology Therapeutics by Geographic Region - France, Germany, Italy, UK and Rest of Europe Markets - Independent Analysis of Annual Sales in US$ Million for Years 2020 through 2027 and % CAGR
Europe Historic Review for Rheumatology Therapeutics by Geographic Region - France, Germany, Italy, UK and Rest of Europe Markets - Independent Analysis of Annual Sales in US$ Million for Years 2012 through 2019 and % CAGR
Europe 15-Year Perspective for Rheumatology Therapeutics by Geographic Region - Percentage Breakdown of Value Sales for France, Germany, Italy, UK and Rest of Europe Markets for Years 2012, 2020 & 2027
Europe Current & Future Analysis for Rheumatology Therapeutics by Drug Class - Disease Modifying Anti-Rheumatic Drugs (DMARDs), Non-Steroidal Anti-Inflammatory Drugs (Nsaids), Corticosteroids, Uric Acid Drugs and Other Drug Classes - Independent Analysis of Annual Sales in US$ Million for the Years 2020 through 2027 and % CAGR
Europe Historic Review for Rheumatology Therapeutics by Drug Class - Disease Modifying Anti-Rheumatic Drugs (DMARDs), Non-Steroidal Anti-Inflammatory Drugs (Nsaids), Corticosteroids, Uric Acid Drugs and Other Drug Classes Markets - Independent Analysis of Annual Sales in US$ Million for Years 2012 through 2019 and % CAGR
Europe 15-Year Perspective for Rheumatology Therapeutics by Drug Class - Percentage Breakdown of Value Sales for Disease Modifying Anti-Rheumatic Drugs (DMARDs), Non-Steroidal Anti-Inflammatory Drugs (Nsaids), Corticosteroids, Uric Acid Drugs and Other Drug Classes for the Years 2012, 2020 & 2027
Europe Current & Future Analysis for Rheumatology Therapeutics by Disease Indication - Rheumatoid Arthritis (RA), Osteoarthritis (OA), Gout, Ankylosing Spondylitis, Psoriatic Arthritis and Other Disease Indications - Independent Analysis of Annual Sales in US$ Million for the Years 2020 through 2027 and % CAGR
Europe Historic Review for Rheumatology Therapeutics by Disease Indication - Rheumatoid Arthritis (RA), Osteoarthritis (OA), Gout, Ankylosing Spondylitis, Psoriatic Arthritis and Other Disease Indications Markets - Independent Analysis of Annual Sales in US$ Million for Years 2012 through 2019 and % CAGR
Europe 15-Year Perspective for Rheumatology Therapeutics by Disease Indication - Percentage Breakdown of Value Sales for Rheumatoid Arthritis (RA), Osteoarthritis (OA), Gout, Ankylosing Spondylitis, Psoriatic Arthritis and Other Disease Indications for the Years 2012, 2020 & 2027
Europe Current & Future Analysis for Rheumatology Therapeutics by Route Of Administration - Oral Route, Parenteral Route and Topical - Independent Analysis of Annual Sales in US$ Million for the Years 2020 through 2027 and % CAGR
Europe Historic Review for Rheumatology Therapeutics by Route Of Administration - Oral Route, Parenteral Route and Topical Markets - Independent Analysis of Annual Sales in US$ Million for Years 2012 through 2019 and % CAGR
Europe 15-Year Perspective for Rheumatology Therapeutics by Route Of Administration - Percentage Breakdown of Value Sales for Oral Route, Parenteral Route and Topical for the Years 2012, 2020 & 2027
Europe Current & Future Analysis for Rheumatology Therapeutics by Distribution Channel - Hospital Pharmacy, Retail Pharmacy and Online Pharmacy - Independent Analysis of Annual Sales in US$ Million for the Years 2020 through 2027 and % CAGR
Europe Historic Review for Rheumatology Therapeutics by Distribution Channel - Hospital Pharmacy, Retail Pharmacy and Online Pharmacy Markets - Independent Analysis of Annual Sales in US$ Million for Years 2012 through 2019 and % CAGR
Europe 15-Year Perspective for Rheumatology Therapeutics by Distribution Channel - Percentage Breakdown of Value Sales for Hospital Pharmacy, Retail Pharmacy and Online Pharmacy for the Years 2012, 2020 & 2027
FRANCE
France Current & Future Analysis for Rheumatology Therapeutics by Drug Class - Disease Modifying Anti-Rheumatic Drugs (DMARDs), Non-Steroidal Anti-Inflammatory Drugs (Nsaids), Corticosteroids, Uric Acid Drugs and Other Drug Classes - Independent Analysis of Annual Sales in US$ Million for the Years 2020 through 2027 and % CAGR
France Historic Review for Rheumatology Therapeutics by Drug Class - Disease Modifying Anti-Rheumatic Drugs (DMARDs), Non-Steroidal Anti-Inflammatory Drugs (Nsaids), Corticosteroids, Uric Acid Drugs and Other Drug Classes Markets - Independent Analysis of Annual Sales in US$ Million for Years 2012 through 2019 and % CAGR
France 15-Year Perspective for Rheumatology Therapeutics by Drug Class - Percentage Breakdown of Value Sales for Disease Modifying Anti-Rheumatic Drugs (DMARDs), Non-Steroidal Anti-Inflammatory Drugs (Nsaids), Corticosteroids, Uric Acid Drugs and Other Drug Classes for the Years 2012, 2020 & 2027
France Current & Future Analysis for Rheumatology Therapeutics by Disease Indication - Rheumatoid Arthritis (RA), Osteoarthritis (OA), Gout, Ankylosing Spondylitis, Psoriatic Arthritis and Other Disease Indications - Independent Analysis of Annual Sales in US$ Million for the Years 2020 through 2027 and % CAGR
France Historic Review for Rheumatology Therapeutics by Disease Indication - Rheumatoid Arthritis (RA), Osteoarthritis (OA), Gout, Ankylosing Spondylitis, Psoriatic Arthritis and Other Disease Indications Markets - Independent Analysis of Annual Sales in US$ Million for Years 2012 through 2019 and % CAGR
France 15-Year Perspective for Rheumatology Therapeutics by Disease Indication - Percentage Breakdown of Value Sales for Rheumatoid Arthritis (RA), Osteoarthritis (OA), Gout, Ankylosing Spondylitis, Psoriatic Arthritis and Other Disease Indications for the Years 2012, 2020 & 2027
France Current & Future Analysis for Rheumatology Therapeutics by Route Of Administration - Oral Route, Parenteral Route and Topical - Independent Analysis of Annual Sales in US$ Million for the Years 2020 through 2027 and % CAGR
France Historic Review for Rheumatology Therapeutics by Route Of Administration - Oral Route, Parenteral Route and Topical Markets - Independent Analysis of Annual Sales in US$ Million for Years 2012 through 2019 and % CAGR
France 15-Year Perspective for Rheumatology Therapeutics by Route Of Administration - Percentage Breakdown of Value Sales for Oral Route, Parenteral Route and Topical for the Years 2012, 2020 & 2027
France Current & Future Analysis for Rheumatology Therapeutics by Distribution Channel - Hospital Pharmacy, Retail Pharmacy and Online Pharmacy - Independent Analysis of Annual Sales in US$ Million for the Years 2020 through 2027 and % CAGR
France Historic Review for Rheumatology Therapeutics by Distribution Channel - Hospital Pharmacy, Retail Pharmacy and Online Pharmacy Markets - Independent Analysis of Annual Sales in US$ Million for Years 2012 through 2019 and % CAGR
France 15-Year Perspective for Rheumatology Therapeutics by Distribution Channel - Percentage Breakdown of Value Sales for Hospital Pharmacy, Retail Pharmacy and Online Pharmacy for the Years 2012, 2020 & 2027
GERMANY
Germany Current & Future Analysis for Rheumatology Therapeutics by Drug Class - Disease Modifying Anti-Rheumatic Drugs (DMARDs), Non-Steroidal Anti-Inflammatory Drugs (Nsaids), Corticosteroids, Uric Acid Drugs and Other Drug Classes - Independent Analysis of Annual Sales in US$ Million for the Years 2020 through 2027 and % CAGR
Germany Historic Review for Rheumatology Therapeutics by Drug Class - Disease Modifying Anti-Rheumatic Drugs (DMARDs), Non-Steroidal Anti-Inflammatory Drugs (Nsaids), Corticosteroids, Uric Acid Drugs and Other Drug Classes Markets - Independent Analysis of Annual Sales in US$ Million for Years 2012 through 2019 and % CAGR
Germany 15-Year Perspective for Rheumatology Therapeutics by Drug Class - Percentage Breakdown of Value Sales for Disease Modifying Anti-Rheumatic Drugs (DMARDs), Non-Steroidal Anti-Inflammatory Drugs (Nsaids), Corticosteroids, Uric Acid Drugs and Other Drug Classes for the Years 2012, 2020 & 2027
Germany Current & Future Analysis for Rheumatology Therapeutics by Disease Indication - Rheumatoid Arthritis (RA), Osteoarthritis (OA), Gout, Ankylosing Spondylitis, Psoriatic Arthritis and Other Disease Indications - Independent Analysis of Annual Sales in US$ Million for the Years 2020 through 2027 and % CAGR
Germany Historic Review for Rheumatology Therapeutics by Disease Indication - Rheumatoid Arthritis (RA), Osteoarthritis (OA), Gout, Ankylosing Spondylitis, Psoriatic Arthritis and Other Disease Indications Markets - Independent Analysis of Annual Sales in US$ Million for Years 2012 through 2019 and % CAGR
Germany 15-Year Perspective for Rheumatology Therapeutics by Disease Indication - Percentage Breakdown of Value Sales for Rheumatoid Arthritis (RA), Osteoarthritis (OA), Gout, Ankylosing Spondylitis, Psoriatic Arthritis and Other Disease Indications for the Years 2012, 2020 & 2027
Germany Current & Future Analysis for Rheumatology Therapeutics by Route Of Administration - Oral Route, Parenteral Route and Topical - Independent Analysis of Annual Sales in US$ Million for the Years 2020 through 2027 and % CAGR
Germany Historic Review for Rheumatology Therapeutics by Route Of Administration - Oral Route, Parenteral Route and Topical Markets - Independent Analysis of Annual Sales in US$ Million for Years 2012 through 2019 and % CAGR
Germany 15-Year Perspective for Rheumatology Therapeutics by Route Of Administration - Percentage Breakdown of Value Sales for Oral Route, Parenteral Route and Topical for the Years 2012, 2020 & 2027
Germany Current & Future Analysis for Rheumatology Therapeutics by Distribution Channel - Hospital Pharmacy, Retail Pharmacy and Online Pharmacy - Independent Analysis of Annual Sales in US$ Million for the Years 2020 through 2027 and % CAGR
Germany Historic Review for Rheumatology Therapeutics by Distribution Channel - Hospital Pharmacy, Retail Pharmacy and Online Pharmacy Markets - Independent Analysis of Annual Sales in US$ Million for Years 2012 through 2019 and % CAGR
Germany 15-Year Perspective for Rheumatology Therapeutics by Distribution Channel - Percentage Breakdown of Value Sales for Hospital Pharmacy, Retail Pharmacy and Online Pharmacy for the Years 2012, 2020 & 2027
ITALY
Italy Current & Future Analysis for Rheumatology Therapeutics by Drug Class - Disease Modifying Anti-Rheumatic Drugs (DMARDs), Non-Steroidal Anti-Inflammatory Drugs (Nsaids), Corticosteroids, Uric Acid Drugs and Other Drug Classes - Independent Analysis of Annual Sales in US$ Million for the Years 2020 through 2027 and % CAGR
Italy Historic Review for Rheumatology Therapeutics by Drug Class - Disease Modifying Anti-Rheumatic Drugs (DMARDs), Non-Steroidal Anti-Inflammatory Drugs (Nsaids), Corticosteroids, Uric Acid Drugs and Other Drug Classes Markets - Independent Analysis of Annual Sales in US$ Million for Years 2012 through 2019 and % CAGR
Italy 15-Year Perspective for Rheumatology Therapeutics by Drug Class - Percentage Breakdown of Value Sales for Disease Modifying Anti-Rheumatic Drugs (DMARDs), Non-Steroidal Anti-Inflammatory Drugs (Nsaids), Corticosteroids, Uric Acid Drugs and Other Drug Classes for the Years 2012, 2020 & 2027
Italy Current & Future Analysis for Rheumatology Therapeutics by Disease Indication - Rheumatoid Arthritis (RA), Osteoarthritis (OA), Gout, Ankylosing Spondylitis, Psoriatic Arthritis and Other Disease Indications - Independent Analysis of Annual Sales in US$ Million for the Years 2020 through 2027 and % CAGR
Italy Historic Review for Rheumatology Therapeutics by Disease Indication - Rheumatoid Arthritis (RA), Osteoarthritis (OA), Gout, Ankylosing Spondylitis, Psoriatic Arthritis and Other Disease Indications Markets - Independent Analysis of Annual Sales in US$ Million for Years 2012 through 2019 and % CAGR
Italy 15-Year Perspective for Rheumatology Therapeutics by Disease Indication - Percentage Breakdown of Value Sales for Rheumatoid Arthritis (RA), Osteoarthritis (OA), Gout, Ankylosing Spondylitis, Psoriatic Arthritis and Other Disease Indications for the Years 2012, 2020 & 2027
Italy Current & Future Analysis for Rheumatology Therapeutics by Route Of Administration - Oral Route, Parenteral Route and Topical - Independent Analysis of Annual Sales in US$ Million for the Years 2020 through 2027 and % CAGR
Italy Historic Review for Rheumatology Therapeutics by Route Of Administration - Oral Route, Parenteral Route and Topical Markets - Independent Analysis of Annual Sales in US$ Million for Years 2012 through 2019 and % CAGR
Italy 15-Year Perspective for Rheumatology Therapeutics by Route Of Administration - Percentage Breakdown of Value Sales for Oral Route, Parenteral Route and Topical for the Years 2012, 2020 & 2027
Italy Current & Future Analysis for Rheumatology Therapeutics by Distribution Channel - Hospital Pharmacy, Retail Pharmacy and Online Pharmacy - Independent Analysis of Annual Sales in US$ Million for the Years 2020 through 2027 and % CAGR
Italy Historic Review for Rheumatology Therapeutics by Distribution Channel - Hospital Pharmacy, Retail Pharmacy and Online Pharmacy Markets - Independent Analysis of Annual Sales in US$ Million for Years 2012 through 2019 and % CAGR
Italy 15-Year Perspective for Rheumatology Therapeutics by Distribution Channel - Percentage Breakdown of Value Sales for Hospital Pharmacy, Retail Pharmacy and Online Pharmacy for the Years 2012, 2020 & 2027
UNITED KINGDOM
UK Current & Future Analysis for Rheumatology Therapeutics by Drug Class - Disease Modifying Anti-Rheumatic Drugs (DMARDs), Non-Steroidal Anti-Inflammatory Drugs (Nsaids), Corticosteroids, Uric Acid Drugs and Other Drug Classes - Independent Analysis of Annual Sales in US$ Million for the Years 2020 through 2027 and % CAGR
UK Historic Review for Rheumatology Therapeutics by Drug Class - Disease Modifying Anti-Rheumatic Drugs (DMARDs), Non-Steroidal Anti-Inflammatory Drugs (Nsaids), Corticosteroids, Uric Acid Drugs and Other Drug Classes Markets - Independent Analysis of Annual Sales in US$ Million for Years 2012 through 2019 and % CAGR
UK 15-Year Perspective for Rheumatology Therapeutics by Drug Class - Percentage Breakdown of Value Sales for Disease Modifying Anti-Rheumatic Drugs (DMARDs), Non-Steroidal Anti-Inflammatory Drugs (Nsaids), Corticosteroids, Uric Acid Drugs and Other Drug Classes for the Years 2012, 2020 & 2027
UK Current & Future Analysis for Rheumatology Therapeutics by Disease Indication - Rheumatoid Arthritis (RA), Osteoarthritis (OA), Gout, Ankylosing Spondylitis, Psoriatic Arthritis and Other Disease Indications - Independent Analysis of Annual Sales in US$ Million for the Years 2020 through 2027 and % CAGR
UK Historic Review for Rheumatology Therapeutics by Disease Indication - Rheumatoid Arthritis (RA), Osteoarthritis (OA), Gout, Ankylosing Spondylitis, Psoriatic Arthritis and Other Disease Indications Markets - Independent Analysis of Annual Sales in US$ Million for Years 2012 through 2019 and % CAGR
UK 15-Year Perspective for Rheumatology Therapeutics by Disease Indication - Percentage Breakdown of Value Sales for Rheumatoid Arthritis (RA), Osteoarthritis (OA), Gout, Ankylosing Spondylitis, Psoriatic Arthritis and Other Disease Indications for the Years 2012, 2020 & 2027
UK Current & Future Analysis for Rheumatology Therapeutics by Route Of Administration - Oral Route, Parenteral Route and Topical - Independent Analysis of Annual Sales in US$ Million for the Years 2020 through 2027 and % CAGR
UK Historic Review for Rheumatology Therapeutics by Route Of Administration - Oral Route, Parenteral Route and Topical Markets - Independent Analysis of Annual Sales in US$ Million for Years 2012 through 2019 and % CAGR
UK 15-Year Perspective for Rheumatology Therapeutics by Route Of Administration - Percentage Breakdown of Value Sales for Oral Route, Parenteral Route and Topical for the Years 2012, 2020 & 2027
UK Current & Future Analysis for Rheumatology Therapeutics by Distribution Channel - Hospital Pharmacy, Retail Pharmacy and Online Pharmacy - Independent Analysis of Annual Sales in US$ Million for the Years 2020 through 2027 and % CAGR
UK Historic Review for Rheumatology Therapeutics by Distribution Channel - Hospital Pharmacy, Retail Pharmacy and Online Pharmacy Markets - Independent Analysis of Annual Sales in US$ Million for Years 2012 through 2019 and % CAGR
UK 15-Year Perspective for Rheumatology Therapeutics by Distribution Channel - Percentage Breakdown of Value Sales for Hospital Pharmacy, Retail Pharmacy and Online Pharmacy for the Years 2012, 2020 & 2027
REST OF EUROPE
Rest of Europe Current & Future Analysis for Rheumatology Therapeutics by Drug Class - Disease Modifying Anti-Rheumatic Drugs (DMARDs), Non-Steroidal Anti-Inflammatory Drugs (Nsaids), Corticosteroids, Uric Acid Drugs and Other Drug Classes - Independent Analysis of Annual Sales in US$ Million for the Years 2020 through 2027 and % CAGR
Rest of Europe Historic Review for Rheumatology Therapeutics by Drug Class - Disease Modifying Anti-Rheumatic Drugs (DMARDs), Non-Steroidal Anti-Inflammatory Drugs (Nsaids), Corticosteroids, Uric Acid Drugs and Other Drug Classes Markets - Independent Analysis of Annual Sales in US$ Million for Years 2012 through 2019 and % CAGR
Rest of Europe 15-Year Perspective for Rheumatology Therapeutics by Drug Class - Percentage Breakdown of Value Sales for Disease Modifying Anti-Rheumatic Drugs (DMARDs), Non-Steroidal Anti-Inflammatory Drugs (Nsaids), Corticosteroids, Uric Acid Drugs and Other Drug Classes for the Years 2012, 2020 & 2027
Rest of Europe Current & Future Analysis for Rheumatology Therapeutics by Disease Indication - Rheumatoid Arthritis (RA), Osteoarthritis (OA), Gout, Ankylosing Spondylitis, Psoriatic Arthritis and Other Disease Indications - Independent Analysis of Annual Sales in US$ Million for the Years 2020 through 2027 and % CAGR
Rest of Europe Historic Review for Rheumatology Therapeutics by Disease Indication - Rheumatoid Arthritis (RA), Osteoarthritis (OA), Gout, Ankylosing Spondylitis, Psoriatic Arthritis and Other Disease Indications Markets - Independent Analysis of Annual Sales in US$ Million for Years 2012 through 2019 and % CAGR
Rest of Europe 15-Year Perspective for Rheumatology Therapeutics by Disease Indication - Percentage Breakdown of Value Sales for Rheumatoid Arthritis (RA), Osteoarthritis (OA), Gout, Ankylosing Spondylitis, Psoriatic Arthritis and Other Disease Indications for the Years 2012, 2020 & 2027
Rest of Europe Current & Future Analysis for Rheumatology Therapeutics by Route Of Administration - Oral Route, Parenteral Route and Topical - Independent Analysis of Annual Sales in US$ Million for the Years 2020 through 2027 and % CAGR
Rest of Europe Historic Review for Rheumatology Therapeutics by Route Of Administration - Oral Route, Parenteral Route and Topical Markets - Independent Analysis of Annual Sales in US$ Million for Years 2012 through 2019 and % CAGR
Rest of Europe 15-Year Perspective for Rheumatology Therapeutics by Route Of Administration - Percentage Breakdown of Value Sales for Oral Route, Parenteral Route and Topical for the Years 2012, 2020 & 2027
Rest of Europe Current & Future Analysis for Rheumatology Therapeutics by Distribution Channel - Hospital Pharmacy, Retail Pharmacy and Online Pharmacy - Independent Analysis of Annual Sales in US$ Million for the Years 2020 through 2027 and % CAGR
Rest of Europe Historic Review for Rheumatology Therapeutics by Distribution Channel - Hospital Pharmacy, Retail Pharmacy and Online Pharmacy Markets - Independent Analysis of Annual Sales in US$ Million for Years 2012 through 2019 and % CAGR
Rest of Europe 15-Year Perspective for Rheumatology Therapeutics by Distribution Channel - Percentage Breakdown of Value Sales for Hospital Pharmacy, Retail Pharmacy and Online Pharmacy for the Years 2012, 2020 & 2027
ASIA-PACIFIC
Asia-Pacific Current & Future Analysis for Rheumatology Therapeutics by Drug Class - Disease Modifying Anti-Rheumatic Drugs (DMARDs), Non-Steroidal Anti-Inflammatory Drugs (Nsaids), Corticosteroids, Uric Acid Drugs and Other Drug Classes - Independent Analysis of Annual Sales in US$ Million for the Years 2020 through 2027 and % CAGR
Asia-Pacific Historic Review for Rheumatology Therapeutics by Drug Class - Disease Modifying Anti-Rheumatic Drugs (DMARDs), Non-Steroidal Anti-Inflammatory Drugs (Nsaids), Corticosteroids, Uric Acid Drugs and Other Drug Classes Markets - Independent Analysis of Annual Sales in US$ Million for Years 2012 through 2019 and % CAGR
Asia-Pacific 15-Year Perspective for Rheumatology Therapeutics by Drug Class - Percentage Breakdown of Value Sales for Disease Modifying Anti-Rheumatic Drugs (DMARDs), Non-Steroidal Anti-Inflammatory Drugs (Nsaids), Corticosteroids, Uric Acid Drugs and Other Drug Classes for the Years 2012, 2020 & 2027
Asia-Pacific Current & Future Analysis for Rheumatology Therapeutics by Disease Indication - Rheumatoid Arthritis (RA), Osteoarthritis (OA), Gout, Ankylosing Spondylitis, Psoriatic Arthritis and Other Disease Indications - Independent Analysis of Annual Sales in US$ Million for the Years 2020 through 2027 and % CAGR
Asia-Pacific Historic Review for Rheumatology Therapeutics by Disease Indication - Rheumatoid Arthritis (RA), Osteoarthritis (OA), Gout, Ankylosing Spondylitis, Psoriatic Arthritis and Other Disease Indications Markets - Independent Analysis of Annual Sales in US$ Million for Years 2012 through 2019 and % CAGR
Asia-Pacific 15-Year Perspective for Rheumatology Therapeutics by Disease Indication - Percentage Breakdown of Value Sales for Rheumatoid Arthritis (RA), Osteoarthritis (OA), Gout, Ankylosing Spondylitis, Psoriatic Arthritis and Other Disease Indications for the Years 2012, 2020 & 2027
Asia-Pacific Current & Future Analysis for Rheumatology Therapeutics by Route Of Administration - Oral Route, Parenteral Route and Topical - Independent Analysis of Annual Sales in US$ Million for the Years 2020 through 2027 and % CAGR
Asia-Pacific Historic Review for Rheumatology Therapeutics by Route Of Administration - Oral Route, Parenteral Route and Topical Markets - Independent Analysis of Annual Sales in US$ Million for Years 2012 through 2019 and % CAGR
Asia-Pacific 15-Year Perspective for Rheumatology Therapeutics by Route Of Administration - Percentage Breakdown of Value Sales for Oral Route, Parenteral Route and Topical for the Years 2012, 2020 & 2027
Asia-Pacific Current & Future Analysis for Rheumatology Therapeutics by Distribution Channel - Hospital Pharmacy, Retail Pharmacy and Online Pharmacy - Independent Analysis of Annual Sales in US$ Million for the Years 2020 through 2027 and % CAGR
Asia-Pacific Historic Review for Rheumatology Therapeutics by Distribution Channel - Hospital Pharmacy, Retail Pharmacy and Online Pharmacy Markets - Independent Analysis of Annual Sales in US$ Million for Years 2012 through 2019 and % CAGR
Asia-Pacific 15-Year Perspective for Rheumatology Therapeutics by Distribution Channel - Percentage Breakdown of Value Sales for Hospital Pharmacy, Retail Pharmacy and Online Pharmacy for the Years 2012, 2020 & 2027
REST OF WORLD
Rest of World Current & Future Analysis for Rheumatology Therapeutics by Drug Class - Disease Modifying Anti-Rheumatic Drugs (DMARDs), Non-Steroidal Anti-Inflammatory Drugs (Nsaids), Corticosteroids, Uric Acid Drugs and Other Drug Classes - Independent Analysis of Annual Sales in US$ Million for the Years 2020 through 2027 and % CAGR
Rest of World Historic Review for Rheumatology Therapeutics by Drug Class - Disease Modifying Anti-Rheumatic Drugs (DMARDs), Non-Steroidal Anti-Inflammatory Drugs (Nsaids), Corticosteroids, Uric Acid Drugs and Other Drug Classes Markets - Independent Analysis of Annual Sales in US$ Million for Years 2012 through 2019 and % CAGR
Rest of World 15-Year Perspective for Rheumatology Therapeutics by Drug Class - Percentage Breakdown of Value Sales for Disease Modifying Anti-Rheumatic Drugs (DMARDs), Non-Steroidal Anti-Inflammatory Drugs (Nsaids), Corticosteroids, Uric Acid Drugs and Other Drug Classes for the Years 2012, 2020 & 2027
Rest of World Current & Future Analysis for Rheumatology Therapeutics by Disease Indication - Rheumatoid Arthritis (RA), Osteoarthritis (OA), Gout, Ankylosing Spondylitis, Psoriatic Arthritis and Other Disease Indications - Independent Analysis of Annual Sales in US$ Million for the Years 2020 through 2027 and % CAGR
Rest of World Historic Review for Rheumatology Therapeutics by Disease Indication - Rheumatoid Arthritis (RA), Osteoarthritis (OA), Gout, Ankylosing Spondylitis, Psoriatic Arthritis and Other Disease Indications Markets - Independent Analysis of Annual Sales in US$ Million for Years 2012 through 2019 and % CAGR
Rest of World 15-Year Perspective for Rheumatology Therapeutics by Disease Indication - Percentage Breakdown of Value Sales for Rheumatoid Arthritis (RA), Osteoarthritis (OA), Gout, Ankylosing Spondylitis, Psoriatic Arthritis and Other Disease Indications for the Years 2012, 2020 & 2027
Rest of World Current & Future Analysis for Rheumatology Therapeutics by Route Of Administration - Oral Route, Parenteral Route and Topical - Independent Analysis of Annual Sales in US$ Million for the Years 2020 through 2027 and % CAGR
Rest of World Historic Review for Rheumatology Therapeutics by Route Of Administration - Oral Route, Parenteral Route and Topical Markets - Independent Analysis of Annual Sales in US$ Million for Years 2012 through 2019 and % CAGR
Rest of World 15-Year Perspective for Rheumatology Therapeutics by Route Of Administration - Percentage Breakdown of Value Sales for Oral Route, Parenteral Route and Topical for the Years 2012, 2020 & 2027
Rest of World Current & Future Analysis for Rheumatology Therapeutics by Distribution Channel - Hospital Pharmacy, Retail Pharmacy and Online Pharmacy - Independent Analysis of Annual Sales in US$ Million for the Years 2020 through 2027 and % CAGR
Rest of World Historic Review for Rheumatology Therapeutics by Distribution Channel - Hospital Pharmacy, Retail Pharmacy and Online Pharmacy Markets - Independent Analysis of Annual Sales in US$ Million for Years 2012 through 2019 and % CAGR
Rest of World 15-Year Perspective for Rheumatology Therapeutics by Distribution Channel - Percentage Breakdown of Value Sales for Hospital Pharmacy, Retail Pharmacy and Online Pharmacy for the Years 2012, 2020 & 2027
Total Companies Profiled: 46

PREVIEW REPORT

YOUR PRIVACY MATTERS!

Our robust permission-based engagement strategy requires a one-time double opt-in and/or re-consent for all users. We will re-establish consent once a year from date of last use. Both these practices exceed GDPR mandates.

What we store: Primary coordinates such as email, company address and phone. In-house developed influencer rank.
How we store: Encrypted and additionally secured by firewalls.
How we use your data: Only to contact you directly. We never share your coordinates with any individual or entity outside our company for any reason.
Privacy queries: Privacy@StrategyR.com